Lareb notes newly reported deaths shortly after vaccination The Pharmacovigilance Centre Lareb announced today that the centre had received a total of 15 reports so far regarding deaths shortly after receiving the COVID-19 vaccinations.
New research in GGD test lanes on spread of coronavirus SARS-CoV-2 RIVM is launching a survey-based study this week on risk factors for the coronavirus SARS-CoV-2. The participants in this study are people who get tested for COVID-19 in a GGD test lane.
80 to 84-year-olds invited for vaccination sooner Starting tomorrow, the first people in the age group from 80-84 years in the Netherlands will receive an invitation from RIVM for a COVID-19 vaccination.
New variants disrupt plans In the past week, from 27 January to 2 February, 28,628 people in the Netherlands reportedly tested positive for COVID-19, a 20% decrease compared to the week of 20 to 26 January.
One person died shortly after COVID-19 vaccination The Pharmacovigilance Centre Lareb announced today that the centre had received a report of death shortly after receiving the Pfizer/BioNTech COVID-19 vaccination in the Netherlands.
Nationwide assessment of SARS-CoV-2 laboratories: very high quality The vast majority of the laboratories analysing COVID-19 tests are performing at the very highest standard of quality.
Increase in number of additives in tobacco products A total of 673 different types of additives are used by manufacturers in their tobacco products (cigarettes, cigars and pipe tobacco) and the number of additives used per tobacco product type incre
Metals in tobacco harmful to health Growing tobacco plants acquire metals from soil, fertilisers, and industrial pollution. Smoking liberates some of these metals from tobacco into smoke to be inhaled by the smoker and bystanders.
Half of the Dutch participate in sport weekly In 2014, 53% of people between the ages of 12 and 80 in the Netherlands participate in some type of sport weekly.
Translation Dutch Health Care Performance Report 2014 available Every four years, RIVM assesses the quality, accessibility and affordability of the Dutch healthcare system.